Niowave, a Michigan-based radioisotope supplier, has broken ground on a $75 million Actinium-225 (Ac-225) production facility in Lansing, MI. The plant is expected to come online in 2028. Ac-225 is used in targeted alpha therapies, a next generation of cancer treatment.
The move follows back-to-back long-term supply agreements with Novartis and AstraZeneca, both signed within the last six months. The facility will house multiple superconducting linear accelerators and employ 70 specialized staffers across R&D, engineering and QA.